Assessing the contribution of rare variants to congenital heart disease through a large scale case-control exome study

3

4	Enrique Audain ^{1,2#} , Anna Wilsdon ^{3#} , Gregor Dombrowsky ^{1,2} , Alejandro Sifrim ⁴ , Jeroen Breckpot ⁴ ,
5	Yasset Perez-Riverol ⁵ , Siobhan Loughna ³ , Allan Daly ⁶ , Pavlos Antoniou ⁶ , Philipp Hofmann ¹ , Amilcar
6	Perez-Riverol ² , Anne-Karin Kahlert ¹ , Ulrike Bauer ⁷ , Thomas Pickardt ⁷ , Sabine Klaassen ^{8,9} , Felix
7	Berger ⁹ , Ingo Daehnert ¹⁰ , Sven Dittrich ¹¹ , Brigitte Stiller ¹² , Hashim Abdul-Khaliq ¹³ , Frances
8	Bu'lock ¹⁴ , Anselm Uebing ^{1,15} , Hans-Heiner Kramer ¹ , Vivek Iyer ⁶ , Lars Allan Larsen ¹⁶ , J David
9	Brook ^{3*} , Marc-Phillip Hitz ^{1,2,6,15*}

- 10 # These authors contributed equally to this work.
- 11 * Joint corresponding authors.
- 12
- 1 Department of Congenital Heart Disease and Pediatric Cardiology, University Hospital of Schleswig-Holstein, Kiel, Germany,
- 2 Institute for Medical Genetics, Klinikum Oldenburg, Oldenburg, Germany.
- 3 School of Life Sciences, University of Nottingham, University Park, Nottingham, United Kingdom
- 4 Department of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium
- 5 European Bioinformatics Institute (EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom
- 6 Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom
- 7 Competence Network for Congenital Heart Defects, Berlin, Germany
- 8 Experimental and Clinical Research Center (ECRC), Charité Universitätsmedizin Berlin and Max Delbrück Center, Berlin, Germany
- 9 Deutsches Herzzentrum der Charité, Dept. of Congenital Heart Disease-Pediatric Cardiology, Berlin, Germany
- 10 Department of Pediatric Cardiology and Congenital Heart Disease, Heart Center, University of Leipzig, Leipzig, Germany
- 11 Department of Pediatric Cardiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
- 12 Department of Congenital Heart Disease and Pediatric Cardiology, University Heart Center Freiburg—Bad Krozingen, Freiburg, Germany
- 13 Department of pediatric Cardiology, Saarland University Hospital, Homburg, Germany
- 14 Congenital and Paediatric Cardiology, East Midlands Congenital Heart Centre and University of Leicester, Glenfield Hospital, United Kingdom
- 15 German Centre for Cardiovascular Research (DZHK), Partner Site Kiel, Germany.
- 16 Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
- 13 14

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

15 **ABSTRACT**

16

17 Several studies have demonstrated the value of large-scale human exome and 18 genome data analysis, to maximise gene discovery in rare diseases. Using this 19 approach, we have analysed the exomes of 4,747 cases and 52,881 controls, to 20 identify single genes and digenic interactions which confer a substantial risk of 21 congenital heart disease (CHD). We identified both rare loss-of-function and missense 22 coding variants in ten genes which reached genome-wide significance (Bonferroni 23 adjusted P < 0.05) and an additional four genes with a significant association at a false 24 discovery rate (FDR) threshold of 5%. We highlight distinct genetic contributions to 25 syndromic and non-syndromic CHD at both single gene and digenic level, by 26 independently analysing probands from these two groups. In addition, by integrative 27 analysis of exome data with single-cell transcriptomics data from human embryonic 28 hearts, we identified cardiac-specific cells as well as putative biological processes 29 underlying the pathogenesis of CHD. In summary, our findings strengthen the 30 association of known CHD genes, and have identified additional novel disease genes 31 and digenic interactions contributing to the aetiology of CHD.

32 Keywords: Congenital Heart Disease; UK Biobank; genetic variants; digenic
33 interactions.

- 34
- 35

36 INTRODUCTION

37

Congenital Heart Disease (CHD) is a global health challenge, affecting ~1-2% of live births worldwide¹. However, despite advances in our understanding of the underlying disease aetiology in recent years, a significant proportion of CHD cases remains unexplained, suggesting that genetic mechanisms and other risk factors remain poorly understood^{2,3}. Recent advances in exome and genome sequencing technologies have opened up new avenues of study and have resulted in novel insights into the genetic and epigenetic mechanisms underlying rare diseases, such as CHD^{4,5}.

45 Previous studies have defined the association of inherited and *de novo* variations as 46 a cause of CHD^{6,7}. In addition, these studies have highlighted the differences between 47 the genetic architecture of syndromic (with extracardiac malformations and/or 48 neurodevelopmental delay) and non-syndromic (isolated) CHD^{6,7}. Continuing 49 collaboration between the scientific community and healthcare teams has driven 50 efforts to integrate and analyse larger cohorts of patients, and has demonstrated the 51 potential of this approach to uncover novel variants and genes associated with CHD⁶⁻ 8. 52

Here, we present a whole exome sequencing analysis of 4,747 CHD cases and 52,881
controls. This is one of the largest cohorts of non-syndromic CHD cases (n=2,929)
studied so far, meaning that we are in an advantageous position to refine our
understanding of the genetic mechanisms underlying non-syndromic CHD specifically.
This is especially important given that the vast majority of individuals with CHD, have
non-syndromic CHD.

59 We used the case-control cohort to investigate both single genes and digenic 60 interactions contributing to CHD. We integrated data obtained in the case-control

study with single-cell transcriptome data obtained from human embryonic hearts⁹. This complementary analysis identified biological processes enriched for genes differentially expressed in cardiac-specific cells, found also significant in our casecontrol analysis. Importantly, the data suggest a difference in cardiac developmental mechanisms between syndromic and non-syndromic CHD.

Taken together, we have identified ten genome-wide significant (*Bonferroni adjusted* P < 0.05) genes, and an additional four genes at *FDR* 5%, which are associated with CHD, as well as a larger contribution of digenic interactions to non-syndromic compared to syndromic CHD.

70

71 RESULTS

72

73 Cohort description and analysis workflow

74 We combined and analysed the exomes of 4,747 CHD cases (aCHD, refers to all CHD 75 cases) and 52,881 controls. CHD cases were further classified into syndromic CHD 76 (sCHD, individuals with extracardiac malformations or neurodevelopmental disability, 77 n=1,818) and non-syndromic CHD (nsCHD, individuals with isolated CHD, n=2,929). 78 All samples and genetic variants were subjected to a sequence of quality control steps 79 to obtain a final cohort of unrelated and matched-ancestry individuals, as well as a set 80 of high-confidence variants for downstream analysis (see Methods, Supplemental 81 Information 1).

We evaluated the distribution of high-confidence loss-of-function (hcLOF) and missense constrained variants (missC) across a spectrum of LOF and missense constrained genes (**Methods**). In addition, we performed gene-based burden testing to identify genes conferring a high risk of CHD, as well as the expression pattern at

single-cell resolution. Lastly, we evaluate the contribution of digenic interactors to
syndromic and non-syndromic CHD. Figure 1 simplifies the workflow followed in this
study to discover novel associations with CHD.

89

90 Distinct pattern of loss-of-function constrained genes identified between sCHD

91 and nsCHD

92 Previous studies have suggested a greater contribution of loss-of-function (LOF) variants to sCHD, compared to non-syndromic forms^{6,7}. To determinate if this holds 93 94 true in this present cohort, we evaluated the burden of rare variants in the sCHD and 95 nsCHD cohort, compared with controls across the per gene spectrum of loss-of-96 function intolerance. Following the approach proposed by the gnomAD consortium¹⁰, 97 we divided 19,923 protein-coding genes into ten bins (~1,900 genes per bin) based 98 on its observed/expected LOF ratio upper fraction (termed LOEUF) and applied a 99 logistic regression model (see **Methods**) to each bin (i.e., gene-set). This allowed us 100 to assess enrichment across three different functional categories of variants (hcLOF,

101 missC and synonymous), stratified by CHD probands (aCHD, sCHD and nsCHD).

102 The highest enrichment was observed in the most LOF constrained genes (bin 1) for 103 hcLOF variants (Figure 2). These variants provided a major contribution to sCHD 104 cases (OR = 2.27, $P < 2 \times 10^{-16}$), and much less so for nsCHD (OR = 1.52, $P = 1.2 \times 10^{-16}$) 105 10⁻¹³). A moderate enrichment was observed for missC variations, suggesting that this 106 class of variants could have a similar (although smaller) functional impact compared 107 to hcLOF variants. Although reduced in magnitude, this same pattern was also 108 observed in the set of genes in the second LOEUF constraint bin, whereas no 109 enrichment was observed towards less LOEUF constrained bins (Figure 2). No

enrichment of synonymous variants was observed across the bins, providing a
negative control set (Figure 2).

When the same analysis was performed across the missense constraint spectrum, assessed by the observed/expected missense ratio upper fraction gene-based metric (termed MOEUF), a similar pattern as described above (higher enrichment in the most missense-constrained genes) was observed (**Supplemental Figure 1**).

These results demonstrate a larger effect of hcLOF compared to missC variants across the LOEUF and MOEUF spectrum, with the major contribution observed in sCHD, compared with nsCHD. Nevertheless, the results suggest that both hcLOF and missC variants are important genetic components contributing to CHD development.

120

121 Gene-based enrichment analysis

To identify genes that confer a significant risk of CHD, we performed a case-control burden analysis by combining rare variants (MAF < 0.001) at the gene level. It has been demonstrated that following a method of collapsing variants within specific genomic regions (e.g., genes), increases the power to discover new associations at low allele frequencies¹¹. Following this principle, we conducted a Fisher's exact test to identify genes with a significant burden of non-synonymous variants in CHD cases compared to controls, and evaluated them independently for sCHD and nsCHD.

As with earlier comparable case-control exome studies^{12–14}, the burden test was performed separately for hcLOF (P_{lof}) and missC (P_{miss}), and the minimal *p-value* observed per gene between these two variant categories was selected as the studywide *p-value* (P). hcLOF variants were defined using the LOFTEE tool¹⁰, whereas missense variants were defined based on different missense deleteriousness prediction scores (see **Methods, Supplemental Figure 2**). Ten genes were identified

135 with significant P, after correcting for multiple testing using the Bonferroni method 136 (Table 1, Supplemental Table 1). Eight genes were associated with sCHD (KMT2A, 137 SMAD4, PTPN11, TAB2, NSD1, BCOR, KAT6A, PBX1) and two were identified 138 through the nsCHD (FLT4 and NOTCH1) analysis. In addition, four genes showed 139 significant associations with CHD at FDR 5% (CTCF, KAT6B, SHOX2, HCAR1). The 140 evaluation of the set of synonymous variants showed a similar distribution of expected 141 vs observed p-values, suggesting no genomic inflation of the test statistic 142 (Supplemental Figure 3).

Of the genes identified as significant in sCHD, *KMT2A* (AD Wiedemann-Steiner syndrome OMIM 159555) showed the highest enrichment (**Figure 3a**). *NOTCH1* (AD Adams-Oliver syndrome 5, Aortic valve disease 1 OMIM 190198) showed the highest number of variations in the nsCHD cohort (**Figure 3b**) and warranted further investigation (companion manuscript).

Other genes reaching a significant level of association included *NSD1* (AD Sotos Syndrome OMIM 606681), *TAB2* (AD Non-Syndromic CHD 2, OMIM 605101), *KAT6A* (AD Arboleda-Tham Syndrome OMIM 601408), *PTPN11* (AD Noonan Syndrome OMIM 176876), *SMAD4* (AD Mhyre Syndrome OMIM 600993), *FLT4* (AD Congenital heart defects, multiple types, 7 OMIM 136352), and the X-linked gene *BCOR* (XLD Syndromic Micropthalmia OMIM 300485). They have all been previously described in the context of CHD, and our results corroborate these findings.

The association of *PBX1* (AD Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay OMIM 176310), *CTCF* (AD Intellectual developmental disorder, autosomal dominant 21 OMIM 604167) and *KAT6B* (AD Genitopatellar syndrome and SBBYSS syndrome OMIM 605880) with CHD (**Table 1**) have been previously reported in isolated cases

160 or small patient cohorts, and our results add further evidence for an association with161 CHD.

HCAR1 (OMIM 606923) and *SHOX2* (OMIM 602504) have not previously been
associated with CHD at a genome-wide level. However, both genes were significantly
associated with nsCHD at *FDR* 5% (**Figure 3b**).

165

166 **Differentially expressed genes in cardiac-specific cells show a distinct** 167 **enrichment pattern in syndromic and non-syndromic CHD**

168 Previous studies have revealed significant levels of expression in the heart of genes 169 associated with CHD^{7,8}. By using publicly accessible bulk RNAseg data¹⁵ (**Methods**), 170 we consistently showed that genes with significant level of association in our case-171 control analysis also showed high expression in cardiac tissues (Supplemental 172 Figure 4). Moreover, syndromic CHD genes showed a systematic elevated expression in other tissues (e.g., brain and kidney), compared to non-syndromic CHD 173 174 (Supplemental Figure 5). The difference in expression patterns between these two groups was negligible in the heart, though (P > 0.05, Wilcoxon test; **Supplemental** 175 176 Figure 5). Despite its relevance, bulk RNAseq data analysis does not stretch as far 177 as the delineation of expression patterns at the cellular level.

To accomplish this, we assessed the mutational burden of rare non-synonymous variants (hcLOF and missC) within differentially expressed genes (DEGs) in cardiacspecific cells. We meta-analysed the exome data with a publicly available human heart transcriptomic dataset generated from early developmental stages of the human heart (6.5 and 7 weeks post-conception)⁹. Using the logistic regression framework mentioned above, we performed gene-set enrichment analysis on DEGs defined on 15 distinct cardiac cell clusters (C0-C14) reported by Asp *et al*⁹. Both hcLOF and

185 missC mutations were evaluated independently and the analysis was stratified further 186 by proband CHD status versus controls (aCHD, sCHD and nsCHD, **Figure 4**).

187 Five cardiac-specific cell clusters were found significantly enriched (Bonferroni 188 adjusted P < 0.05) for hcLOF variations when analysing aCHD probands vs controls 189 (Figure 4): Smooth muscle cells (C5), Cardiac neural crest cells (C14), Epicardium-190 derived cells (C3), Capillary endothelium (C0) and Atrial cardiomyocytes (C7). 191 Enrichment of hcLOF variants for DEGs in Smooth muscle cells (C5) showed a 192 significant contribution to both sCHD and nsCHD. Cardiac neural crest cells (C14) and 193 Atrial cardiomyocytes (C7) contributed to sCHD in the main, whereas the cluster of 194 Capillary endothelium cells was significantly enriched in nsCHD versus controls 195 (Figure 4).

A similar enrichment pattern was observed when analysing the set of missC variants (**Supplemental Figure 6**). In addition to the Capillary endothelium (C0), Smooth muscle cells (C5), Atrial cardiomyocytes (C7) and Cardiac neural crest cells (C14) clusters; which were also found significantly enriched for hcLOF variants; two other cardiac-specific cell clusters showed a significant burden of missC variants in CHD cases (aCHD) compared to controls: Endothelium/pericytes cells (C10) and Fibroblast cells (C2).

The synonymous variants set was used as a negative control and did not identify enrichment in any clusters evaluated (Bonferroni adjusted P > 0.05, **Supplemental Figure 7**).

206 Together, these results provide valuable evidence regarding the possible mechanisms207 involved in the pathogenesis of CHD.

208

210 Gene Ontology (GO) enrichment analysis

To provide additional supporting evidence for our previous findings, we performed Gene Ontology (GO) enrichment analysis to identify relationships between the enriched DEGs in cardiac-specific cell clusters to biological processes. We analysed the set of DEGs with an unadjusted P < 0.01 (Fisher Exact test) identified in the casecontrol burden analysis within the cell clusters showing enrichment in either the aCHD,

sCHD or nsCHD analysis (**Supplemental Figure 8**).

Among the DEGs in cardiac-specific cells evaluated with the Enrichr tool¹⁶ (see 217 218 **Methods**), four clusters showed at least one GO term with FDR < 1%. The data 219 suggested that cell cluster C7 (Atrial cardiomyocytes, **Supplemental Figure 8a**) was 220 mainly associated with biological processes involved in developing cardiac muscle 221 tissue, and the observed signal was driven by NKX2-5, MYH6, MYOCD, PKP2, BMP7, 222 ANKRD1 and ACTC1. DEGs in C0 (Capillary endothelium, **Supplemental Figure 8b**) 223 showed enrichment for vasculogenesis, with contribution from KDR, NOTCH1 and 224 RASIP1. C5 (Smooth muscle cells, **Supplemental Figure 8c**) was associated with 225 extracellular matrix organisation processes, with a noteworthy contribution of genes that contain a collagen-like domain (e.g., COL14A1 and COL1A2), as well as ELN and 226 227 FBN2. DEGs in C10 (Endothelium and pericyte cells, Supplemental Figure 8d), 228 demonstrated the higher enrichment of missC variants (Supplemental Figure 6), and 229 enrichment of biological process involved in the cellular response to vascular 230 endothelial growth factor stimulus and the regulation of cell migration as part of 231 sprouting angiogenesis. DLL4, FLT4, KDR, MEOX2 and NOTCH1 all contributed to 232 this cluster.

233

235 Contribution of digenic interactions to syndromic and non-syndromic CHD

Next, we studied the contribution of digenic interactions to CHD using the RareComb¹⁷ framework (**see Methods**). Our analysis revealed a total of 2,083 digenic pairs significantly enriched for hcLOF and/or missC variants in CHD cases (aCHD) compared to controls at *FDR* 1% (**Figure 5a, Supplemental Table 2**). The data suggested that a significantly higher proportion of digenic interactors contributed to non-syndromic (n=810) forms of CHD ($P = 6.7 \times 10^{-3}$, proportion Z-test, **Figure 5a**) compared to syndromic forms (n=433).

The rate of a gene being observed in a digenic pair showed no correlation (r2 < 0.2) with its coding sequence (CDS) length (**Supplemental figure 9a**). Thus, the digenic interactions implicated by our data does not appear to be biased by an increased mutation rate of larger genes.

247 A significantly lower LOEUF was observed in the genes forming digenic pairs 248 contributing to syndromic CHD compared to non-syndromic CHD (Figure 5b). A 249 similar pattern was observed by comparing the distribution of MOEUF (Supplemental 250 figure 9b), whereas no significant differences were observed when analysing the 251 observed/expected synonymous upper fraction ratio metric (SOEUF, Supplemental 252 figure 9c). Thus, our data suggest that digenic pairs show similar correlation between 253 loss-of-function intolerance and sCHD as we observed for single genes (Figure 2b). 254 We hypothesized that if genes in the digenic gene-sets are causative of CHD in our 255 patient cohort, we would expect that they are enriched for known CHD genes. To test

257 sCHD and nsCHD and curated lists of genes known to cause CHD in patients⁸. We 258 observed significant enrichment of known CHD disease genes in all three digenic lists

this hypothesis, we calculated the overlap between genes in the digenic lists aCHD,

259 (**Figure 5c**).

To investigate if digenic pairs interact at a systems level, we generated protein-protein interaction (PPI) networks using data from STRING¹⁸. Networks of 1,929 nodes/3,587 edges, 1,042 nodes/882 edges and 610 nodes/307 edges were generated for aCHD, nsCHD and sCHD digenic lists, respectively (**Figure 5d, Supplemental Figure 10**). Analysis of the networks showed that nsCHD and sCHD digenic gene-lists interact in physical networks with PPI enrichment values of 1.78 ($P < 1.0 \times 10^{-16}$) and 1.51 (P =8.3 x 10⁻¹²), respectively.

267 To test if the genes in digenic pairs share the same function, we performed a simple 268 overlap test to see how many digenic pairs show direct (1st degree) interaction in the 269 network. The results show that only very few pairs interact directly at the protein level 270 (Figure 5e). Finally, to determine the degree of separation between digenic pairs in 271 each network, we calculated the length of the shortest path between genes in each 272 pair. This analysis showed that the median of the shortest path between digenic pairs 273 is 5 and 6 for the sCHD and nsCHD networks, respectively (Figure 5f, Supplemental 274 Figure 11).

In summary, our analyses suggest that the digenic pairs interact at systems level in
complex PPI networks, with a high degree of separation between the genes in each
digenic pair.

278

279 **DISCUSSION**

280

In this study, we amassed 57,628 human exomes and conducted both a gene- and gene-set centred case-control burden analysis to increase our understanding of the genetic causes of CHD. After quality control at the sample and variant level, we provide a comprehensive CHD case-control cohort with unrelated and ancestry-

285 matched individuals. Specifically, the availability of detailed phenotype data allowed 286 us to explore the differences between syndromic and non-syndromic forms of CHD. By utilising gene-level constraint information¹⁰, we investigated the contribution and 287 288 properties of loss-of-function and missense constraint variants independently for all 289 CHD cases, as well as syndromic and non-syndromic CHD independently. Like earlier 290 comparable studies^{6,7}, our results revealed a higher contribution of LOF variants to 291 CHD compared to missense variants, confirming that this type of variation represents 292 the largest driver. Subsequently, the analysis of syndromic cases revealed a higher 293 burden of LOF mutations when compared with the non-syndromic cohort. This effect 294 was mainly a result of the contribution of genes with a higher intolerance to loss-of-295 function variations. This same pattern was also observed when analysing the genes 296 based on missense constraint.

297

298 We next assessed the contribution to CHD at the gene level, by performing a gene-299 based case-control burden analysis. Our analysis revealed ten genes that reached 300 genome-wide significant levels of association with CHD (NSD1¹⁹, TAB2²⁰, KAT6A²¹, PTPN11²², CTCF²³, SMAD4²⁴, FLT4²⁵, NOTCH1^{26,27}, BCOR²⁸ and KMT2A²⁹). 301 302 Previous studies have associated these genes as a cause of CHD, and our results 303 confirm this association (**Table 1**). Furthermore, four candidate genes (*PBX1, SHOX2*, 304 KAT6B. HCAR1) were found contributing to both syndromic and non-syndromic CHD 305 at FDR 5%. To our knowledge, these genes have been either not previously 306 associated with, or have only been briefly described in the context of CHD.

307

308 *PBX1* has been primarily associated with congenital abnormalities of the kidney and 309 urinary tract (CAKUT)³⁰; however, previous studies have reported isolated cases

carrying *de novo* missense variations leading to syndromic CHD^{30,31}. In line with these 310 311 early reports, our analysis revealed a significant burden of missense constrained 312 variants in *PBX1* in syndromic CHD patients (**Table 1**). It has also been demonstrated 313 that deficiency of *Pbx1* impacts branchial arch artery patterning and results in the failure of cardiac outflow tract septation³². Interestingly, this gene was also found to 314 315 be differentially expressed in Epicardium and Smooth muscle cells (Supplemental 316 Figure 12). Together our findings suggest that *PBX1* contributes significantly to 317 syndromic forms of CHD.

318

319 SHOX2 was significantly enriched (at FDR 5%) in the nsCHD cohort, for missC 320 variants (Table 1). Recent studies in animal models have demonstrated that the Shox2 321 null mice are embryonic-lethal³³. Cardiovascular defects identified in these mice 322 included an abnormally low heartbeat rate, a severely hypoplastic Sinoatrial Node 323 (SAN), hypoplastic or absent sinus valves³³, and other atrial abnormalities (e.g., 324 enlarged atrial chamber and thinner atrial wall). Subsequently, SHOX2 has been 325 described as playing a key role in developing the Sinoatrial Node^{33,34}. In addition, 326 SHOX2 was identified as a significant DEG in atrial cardiomyocytes (Supplemental 327 Figure 12), providing further supporting evidence of its role in heart development, 328 most likely by regulating the activity of *NXK2-5*^{33,35} and *TBX5*³⁶. These results imply 329 that SHOX2 is a plausible novel non-syndromic CHD gene.

330

Truncating variants in the Lysine Acetyltransferase 6B gene (*KAT6B*) have been
associated with Say–Barber–Biesecker–Young–Simpson Syndrome (SBBYSS,
OMIM 603736) and Genitopatellar Syndrome (GTPTS, OMIM 606170). Heart defects
have been reported as part of the phenotypic spectrum of SBBYSS³⁷. In a recent study

of 32 individuals with *KAT6B* disorder, 47% showed cardiovascular anomalies, mainly atrial septal defects, ventricular septal defects, and patent ductus arteriosus³⁸. Our results have identified that *KAT6B* was differentially expressed in the cluster of atrial cardiomyocytes cells (**Supplemental Figure 12**), which suggests a possible role in the early cardiac development program. Our analysis extends previous findings associating loss-of-function variations in *KAT6B* to sCHD.

341

The Hydroxycarboxylic Acid Receptor 1 (*HCAR1*) does not appear to have been associated with CHD thus far, however our findings suggest this gene may be a novel candidate CHD gene. It was not differentially expressed in any of the cardiac-specific cell clusters analysed.

346

347 By meta-analysing the genomic data with heart single-cell transcriptomic data, we 348 investigated the pattern of expression of DEGs for aCHD, sCHD and nsCHD in a range 349 of cardiac-specific cells. Using Gene Ontology enrichment as a complementary 350 analysis, we identified key gene markers and biological processes associated with CHD. Unlike previous studies^{7,39}, which focused on whole heart bulk-RNA sequencing 351 352 data, the use of transcriptomic data at a single-cell resolution allowed the analysis of 353 candidate gene expression patterns in specific cardiac cell clusters important for early 354 cardiac development. Our analysis highlighted distinct cardiac cell clusters 355 contributing to sCHD and nsCHD. In addition, we demonstrated that missense 356 constrained variants could have a similar functional impact compared to loss-of-357 function variants, although to a lesser degree. For instance, the significant enrichment of sCHD in cardiac neural crest cells (cNCCs) suggests a broader contribution of 358 359 patients affected by syndromic occurrences, not limited to heart development only.

360 Perturbations in the cNCCs migration process can lead to a wide spectrum of human cardio-craniofacial syndromes, including DiGeorge Syndrome (22g11.2 Deletion 361 362 Syndrome, OMIM 188400) and CHARGE (OMIM 214800). The enrichment observed 363 in capillary endothelium and pericyte cells in nsCHD, associated with the 364 vasculogenesis process, suggests that the phenotypic occurrence in these patients is 365 limited to the cardiovascular system rather than affecting a broader spectrum of cells. 366 Whilst the results are promising, they are limited because the currently available human heart single-cell map⁹ is incomplete (e.g., only a few early developmental time 367 368 points). Therefore, future studies integrating mouse and human single-cell heart and 369 whole-embryo data are warranted.

370

371 Contrasting with the study of monogenic causes of CHD, oligogenic factors underlying 372 the disease have been explored to a lesser extent. We took advantage of a newly 373 developed method to study the contribution of digenic interactions (the simplest form of oligogenic) to CHD, in a case-control setting¹⁷. Interestingly, we observed a higher 374 proportion of digenic interactions contributing to non-syndromic compared to 375 376 syndromic CHD. These results contrast with those observed at the gene level, where 377 16 out of 21 genes (~76%) found significant at *FDR* 10% (**Table 1**) were associated 378 with syndromic CHD. These findings imply that sCHD is more likely to have a 379 monogenic aetiology, and oligogenic interactions may be a more important component 380 in the development of non-syndromic forms of CHD.

Functional annotation of subclusters in the networks, generated from nsCHD and
sCHD digenic pairs, indicate that the identified digenic pairs encode proteins involved
in transcriptional regulation, signalling pathways (e.g., BMP/TGF beta signalling and

NOTCH signalling) and tissue structures (e.g. sarcomere and extracellular matrix)
 which are important in heart development^{40–42}.

Our network analyses suggest that rather than interacting within the same subcluster, the digenic pairs interact at systems level, with a high degree of separation between the genes in each pair, thus supporting previous results which suggest that CHD risk factors converge in higher-order developmental networks⁴³.

In summary, we analysed ~57,000 exomes, and complemented this with transcriptomic data at single-cell resolution. The findings have strengthened the association of previously described genes with CHD, identified novel candidate genes, and provide a deeper understanding of the pathophysiological mechanisms underlying CHD at gene and digenic level and the potential different aetiologies between syndromic and non-syndromic CHD.

396

397 METHODS

398

399 Cohort description

400 To create a comprehensive CHD case-control cohort, exome sequencing data from 401 multiple individuals was combined in a unique reference dataset. CHD cases were 402 mainly sequenced as part of an initiative from the German Competence Network for 403 Congenital Heart Defects, the Deciphering Developmental Disorder (DDD) project and 404 the University of Nottingham (UK); controls were sequenced as part of the UK Biobank 405 (UKBB). Samples from the UKBB dataset with phenotype description labelled as 406 Schizophrenia (SCZ), bipolar disorder (BP) or developmental delay (DD) were 407 excluded from the analysis. Accordingly, a small fraction of samples in the UKBB 408 cohort (127 samples), labelled as CHD cases, were included in the analysis. In total,

409 we assembled an exome dataset consisting of 57,628 samples (4,747 CHD cases and
410 52,881 controls).

411

412 Alignment, quality control and variant annotation

The assembled dataset was processed and harmonized using the same alignment (BWA v0.3), calling (GATK v4.0), annotation (VEP v95) and quality control (Hail v0.2) pipelines. **Supplemental Information 1** describes extensively the implementation and results of these methods.

417

418 Defining a set of loss-of-function and missense constraint variants

419 We enriched the dataset for high-confidence loss-of-function (hcLOF) variants and 420 missense constrained (missC) variants. hcLOF variants were annotated as indicated 421 by the LOFTEE tool (https://github.com/konradjk/loftee) with its default parameters 422 and included stop-gained, essential splice and frameshift variants. To define a set of 423 missC variants, we evaluated four state-of-art pathogenicity prediction scores: CADD⁴⁴, MPC⁴⁵, REVEL⁴⁶ and MVP⁴⁷. Specifically, the performance of these scores 424 425 was assessed by classifying benign and pathogenic missense variants (accessed 426 through the ClinVar database, https://www.ncbi.nlm.nih.gov/clinvar) in the context of 427 known CHD genes. In brief, receiver operating characteristic (ROC) analysis was 428 conducted for benign and pathogenic variants within known CHD genes. The analysis 429 was further stratified by splitting the gene set into LOF constraint (LOEUF < 0.35) and 430 LOF non-constraint (LOEUF >= 0.35) genes. A score was defined as a 'good predictor' 431 if achieved an area-under-curve (AUC) > 90% in both evaluated scenarios. Three of 432 these scores (CADD, REVEL and MVP) met this criterion. A missense variant was 433 defined as missC if it was predicted as likely deleterious by at least two of these scores

434 based on the optimal threshold suggested by the ROC analysis (Supplemental
435 Figure 2).

436

437 **Defining rare variants**

Variants were filtered based on the cohort-specific allelic frequency ('internal' AF) as
well as using external datasets. A variant was defined as rare if AF was lower than
0.001 (MAF < 0.001) in the gnomAD database¹⁰ (both exomes v2.1.1 and genomes
v3.0.0), the RUMC cohort⁴⁸, as well as AFs from an *in-house* German exome
sequencing cohort.

443

444 Gene-set enrichment analysis

Generation of gene sets. Gene set-level association analysis was performed to assess
whether an excess of the possible pathogenic variants was enriched for a particular
category of genes (as described below). This procedure was executed for the following
gene sets:

a) LOEUF gene bins: Constraint loss-of-function (LOF) metrics per protein-coding
genes were accessed through gnomAD resource¹⁰. Genes were ranked by their
observed/expected LOF mutation ratio upper fraction (termed LOUEF), and ten bins
with an equal number of genes (~1,900 genes per bin) were defined. Lower values of
LOEUF (e.g., bins 1 and 2) denote most LOF-constrained genes.

b) MOEUF gene bins: Similar as described above for LOEUF genes, but genes were
binned based on their observed/expected missense mutation ratio upper fraction
(termed MOEUF).

457 c) Differentially expressed genes (DEGs) in cardiac-specific cells: DEGs identified in
458 15 distinct cardiac cell clusters reported by Asp *et al*⁹. In brief, genes were determined

459 as significantly differentially expressed in a particular cardiac cell cluster if the 460 averaged log-fold change (logFC) > 0 (upregulated) at FDR 1%.

461

462 Gene set-based association analysis. For each sample within the filtered dataset, we 463 generate a Minimal Allele Count (MAC) metric by aggregating high confidence 464 Genotypes (DP \geq 10, GQ \geq 20 and allelic balance heterozygous \geq 0.2) across the 465 genes within the gene set. Then, a burden logistic regression test was performed using 466 CHD case/control status as response and the five first ancestry principal component 467 and sex as covariates using the Hail function *hl.logistic regression rows*. The analysis 468 was stratified at the sample and variant level. At the sample level, the data was divided 469 based on the syndromic status; three categories were tested: aCHD (all CHD cases 470 vs control), nsCHD (non-syndromic CHD cases vs control) and sCHD (syndromic CHD 471 cases vs control). At variant level, three different groups were evaluated based on the 472 predicted severity of the variants: hcLOF (most severe), missC and synonymous. The 473 synonymous variant set was used as a negative control set at the variant level to 474 evaluate for potential artefacts. The odds ratio (exp (beta coefficient)), 95% confidence 475 interval and *p-value* metrics were used to evaluate significant enrichment.

476

477 Gene-based burden testing

We performed case-control gene-centred burden test analysis to assess genes with significant association with CHD. Fisher Exact test was performed independently for rare (MAF < 0.001) hcLOF and missC variants. To define the significant study-wide *pvalue*, the minimal *p*-*value* (*P*) per gene between these two categories was chosen. The analysis was further stratified by syndromic status to assess the distinct contribution of these categories to CHD. A gene was defined as genome-wide

484 significant if it reached a Bonferroni corrected P < 0.05 and suggested significant if 485 FDR < 5%. In addition, the set of synonymous variants was used as a negative control 486 set since no difference between cases/control is expected on this set of variations 487 (quantile-quantile plots, **Supplemental Figure 3**).

488

489 Expression analysis using bulk RNAseq data

A publicly available human transcriptomic dataset previously described by CardosoMoreira *et al*¹⁵ was used to complement this study. To assess the gene expression
levels in the heart, kidney, brain, and liver; the RPKM matrix hosted in ArrayExpress
(E-MTAB-6814) was used. Gene expression levels were averaged among samples in
the early developmental stages (4-8 weeks-post-conception). Percentile rank per gene
was computed based on the mean expression.

496

497 Gene Ontology enrichment analysis

The R-package *Enrichr* (with the *Biological_Process_2018* database) was used to perform Gene Ontology (GO) enrichment analysis. The analysis was conducted on the differentially expressed genes (DEGs) in cardiac-specific cell clusters, which also showed unadjusted P < 0.01 (Fisher Exact test) from the case-control burden analysis. The evaluated DEGs were previously reported by Asp *et al*⁹ with no additional processing. GO terms with only one overlapping gene were filtered out. A biological process term was considered significant if *FDR* < 1% as reported by the Enrichr tool¹⁵.

505

506 Digenic analysis

507 The digenic analysis was performed using the R-package RareComb¹⁷. RareComb 508 combines inferences statistics with an a priori algorithm to elucidate digenic/oligogenic

509 combinations that are enriched for rare genetic variants. Specifically, we implemented 510 the test *'enrichment_depletion'*, to access digenic pairs significantly enriched with rare 511 (MAF < 0.001) hcLOF and/or missC variations in CHD cases compared to controls 512 (depleted). The analysis was further stratified by syndromic status (aCHD, sCHD or 513 nsCHD vs. controls). Digenic pairs were defined as significant if *FDR* < 1%.

514 Enrichment of known CHD genes was determined by calculating overlap between 515 gene lists. Significant overlap was calculated using hypergeometric statistics. A 516 representation factor was calculated as the number of overlapping genes, divided by 517 the expected number of overlapping genes drawn from two independent groups: 518 RF=x/((n*D)/N), where x=number of overlapping genes, n=genes in group 1, D=genes 519 in group 2, N=protein-coding genes in genome (20,000).

520 Protein-protein interactions (PPIs) were obtained from STRING v.11.5 using genes in 521 the digenic pairs to guery the database. The following parameters were used; network 522 type: physical subnetwork, active interaction sources: experiments, databases (text 523 mining data excluded), minimum required interaction score: 0.400 (medium 524 confidence). PPIs were visualized as a network using CytoScape v3.9.1; nodes 525 represent proteins and edges represent interactions between these proteins. PPI 526 enrichment was analysed using the Analysis tool available in the online version of 527 STRING (https://string-db.org). PPI enrichment was calculated as (observed number 528 of edges) / (expected number of edges) and PPI enrichment P-values were obtained 529 directly from STRING. Length of the shortest path between genes in each digenic pairs, within the nsCHD and sCHD networks was calculated using PesCa⁴⁹ v3.0.8. 530

531

533 Table 1. Top 21 genes in the case-control burden analysis using the Fisher Exact test stratified by 534 syndromic status (sCHD and nsCHD). A total of 16,351 genes were tested per variant type (hcLOF and 535 missC). Analysis: sCHD or nsCHD vs controls. Consequence: denotes the consequence group with the 536 minimal p-value (P). sCHD: number of syndromic cases (heterozygous). nsCHD: number of non-537 syndromic cases (heterozygous). Controls: number of controls (heterozygous). P: the minimal p-value 538 per gene between Plot and Pmiss. P adj (FDR): Adjusted minimal p-value (P) using the B-H method with 539 n = 2*16,351. P adj (Bonferroni): Adjusted minimal p-value (P) using the Bonferroni method with n = 540 2*16,351. In bold are highlighted the ten genes with *Bonferroni adjusted* P < 0.05. Supplemental Table

541 **1** contains the results for all protein-coding genes tested.

Genes	Analysis	Consequence	sCHD	nsCHD	Controls	Р	<i>P</i> adj (FDR)	P adj (Bonferroni)
KMT2A	sCHD	hcLOF	8	0	0	9.76E-13	3.19E-08	3.19E-08
SMAD4	sCHD	missC	11	3	16	2.47E-10	4.04E-06	8.09E-06
NOTCH1	nsCHD	hcLOF	2	7	0	8.48E-10	2.77E-05	2.77E-05
PTPN11	sCHD	missC	11	5	25	8.78E-09	9.57E-05	2.87E-04
TAB2	sCHD	hcLOF	5	1	0	3.13E-08	2.56E-04	1.02E-03
NSD1	sCHD	hcLOF	5	1	1	1.83E-07	1.20E-03	5.98E-03
BCOR	sCHD	hcLOF	4	0	0	9.93E-07	4.06E-03	3.25E-02
KAT6A	sCHD	hcLOF	4	1	0	9.93E-07	4.06E-03	3.25E-02
PBX1	sCHD	missC	6	3	6	7.73E-07	4.06E-03	2.53E-02
FLT4	nsCHD	hcLOF	0	5	0	3.32E-07	5.43E-03	1.09E-02
CTCF	sCHD	missC	4	1	1	4.84E-06	1.58E-02	1.58E-01
КАТ6В	sCHD	hcLOF	4	1	1	4.84E-06	1.58E-02	1.58E-01
SHOX2	nsCHD	missC	1	10	21	1.81E-06	1.98E-02	5.93E-02
HCAR1	nsCHD	missC	2	9	18	4.40E-06	3.60E-02	1.44E-01
ADNP	sCHD	hcLOF	3	0	0	3.15E-05	6.44E-02	1.00E+00
CHD7	sCHD	hcLOF	3	0	0	3.15E-05	6.44E-02	1.00E+00
EP300	sCHD	hcLOF	3	1	0	3.15E-05	6.44E-02	1.00E+00
KMT2D	sCHD	hcLOF	3	0	0	3.15E-05	6.44E-02	1.00E+00
KRT25	sCHD	missC	8	3	31	2.51E-05	6.44E-02	8.19E-01
QRICH1	sCHD	hcLOF	3	0	0	3.15E-05	6.44E-02	1.00E+00
SLC38A9	nsCHD	missC	0	6	6	1.19E-05	7.78E-02	3.89E-01

544 References

- 545 546
- 1. van der Linde, D. et al. Birth Prevalence of Congenital Heart Disease Worldwide. 547 J. Am. Coll. Cardiol. 58, 2241–2247 (2011).
- 548 2. Pierpont, M. E. et al. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement from the American Heart Association. Circulation 138, e653-549 550 e711 (2018).
- 3. Morton, S. U., Quiat, D., Seidman, J. G. & Seidman, C. E. Genomic frontiers in 551 congenital heart disease. Nat. Rev. Cardiol. 1-17 (2021) doi:10.1038/s41569-021-552 553 00587-4.
- 554 4. Homsy, J. et al. De novo mutations in congenital heart disease with 555 neurodevelopmental and other congenital anomalies. Science 350, 1262-6 556 (2015).
- 557 5. Izarzugaza, J. M. G. et al. Systems genetics analysis identifies calcium-signaling 558 defects as novel cause of congenital heart disease. Genome Med. 12, 76 (2020).
- 559 6. Sifrim, A. et al. Distinct genetic architectures for syndromic and nonsyndromic 560 congenital heart defects identified by exome sequencing. Nat. Genet. 48, 1060-5 561 (2016).
- 562 7. Jin, S. C. et al. Contribution of rare inherited and de novo variants in 2,871 563 congenital heart disease probands. Nat. Genet. (2017) doi:10.1038/ng.3970.
- 564 8. Audain, E. et al. Integrative analysis of genomic variants reveals new associations 565 of candidate haploinsufficient genes with congenital heart disease. PLOS Genet. 566 17, e1009679 (2021).
- 567 9. Asp, M. et al. A Spatiotemporal Organ-Wide Gene Expression and Cell Atlas of 568 the Developing Human Heart. Cell 179, 1647-1660.e19 (2019).
- 569 10. Karczewski, K. J. et al. The mutational constraint spectrum quantified from 570 variation in 141,456 humans. Nature 581, 434-443 (2020).
- 571 11. Povysil, G. et al. Rare-variant collapsing analyses for complex traits: guidelines 572 and applications. Nat. Rev. Genet. 20, 747-759 (2019).
- 12. Guo, M. H., Plummer, L., Chan, Y.-M., Hirschhorn, J. N. & Lippincott, M. F. Burden 573 574 Testing of Rare Variants Identified through Exome Sequencing via Publicly 575 Available Control Data. Am. J. Hum. Genet. 103, 522–534 (2018).
- 576 13. Flannick, J. et al. Exome sequencing of 20,791 cases of type 2 diabetes and 577 24,440 controls. Nature 570, 71–76 (2019).
- 578 14. Singh, T., Neale, B. M. & Daly, M. J. Exome sequencing identifies rare coding 579 variants in 10 genes which confer substantial risk for schizophrenia on behalf of 580 the Schizophrenia Exome Meta-Analysis (SCHEMA) Consortium*. medRxiv 581 2020.09.18.20192815 (2020) doi:10.1101/2020.09.18.20192815.
- 582 15. Cardoso-Moreira, M. et al. Gene expression across mammalian organ 583 development. Nature 571, 505-509 (2019).
- 584 16. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web 585 server 2016 update. Nucleic Acids Res. 44, W90-W97 (2016).

- 586 17. Pounraja, V. K. & Girirajan, S. A general framework for identifying oligogenic 587 combinations of rare variants in complex disorders. Genome Res. gr.276348.121 588 (2022) doi:10.1101/gr.276348.121.
- 589 18. Szklarczyk, D. et al. The STRING database in 2021: customizable protein-protein 590 networks, and functional characterization of user-uploaded gene/measurement 591 sets. Nucleic Acids Res. 49, D605–D612 (2021).
- 592 19. Tatton-Brown, K. et al. Genotype-Phenotype Associations in Sotos Syndrome: An 593 Analysis of 266 Individuals with NSD1 Aberrations. Am. J. Hum. Genet. 77, 193-594 204 (2005).
- 595 20. Thienpont, B. et al. Haploinsufficiency of TAB2 Causes Congenital Heart Defects 596 in Humans. Am. J. Hum. Genet. 86, 839-849 (2010).
- 597 21. Urreizti, R. et al. Five new cases of syndromic intellectual disability due to KAT6A 598 mutations: widening the molecular and clinical spectrum. Orphanet J. Rare Dis. 599 15, 44 (2020).
- 600 22. Sarkozy, A. et al. Correlation between PTPN11 gene mutations and congenital 601 heart defects in Noonan and LEOPARD syndromes. J. Med. Genet. 40, 704-8 602 (2003).
- 603 23. Gregor, A. et al. De novo mutations in the genome organizer CTCF cause 604 intellectual disability. Am. J. Hum. Genet. 93, 124-131 (2013).
- 605 24. Lin, A. E. et al. Gain-of-function mutations in SMAD4 cause a distinctive repertoire 606 of cardiovascular phenotypes in patients with Myhre syndrome. Am. J. Med. 607 Genet. A. 170, 2617–31 (2016).
- 608 25. Reuter, M. S. et al. Haploinsufficiency of vascular endothelial growth factor related 609 signaling genes is associated with tetralogy of Fallot. Genet. Med. 21, 1001–1007 610 (2019).
- 611 26. Kerstjens-Frederikse, W. S. et al. Cardiovascular malformations caused by 612 NOTCH1 mutations do not keep left: data on 428 probands with left-sided CHD 613 and their families. Genet. Med. 18, 914-923 (2016).
- 614 27. Garg, V. et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270-615 274 (2005).
- 616 28. Fan, Z. et al. BCOR regulates mesenchymal stem cell function by epigenetic 617 mechanisms. Nat. Cell Biol. 11, 1002-1009 (2009).
- 618 29. Baer, S. et al. Wiedemann-Steiner syndrome as a major cause of syndromic 619 intellectual disability: A study of 33 French cases. Clin. Genet. 94, 141–152 (2018).
- 620 30. Arts, P. et al. Paternal mosaicism for a novel PBX1 mutation associated with 621 recurrent perinatal death: Phenotypic expansion of the PBX1-related syndrome. 622 Am. J. Med. Genet. A. 182, 1273–1277 (2020).
- 623 31. Alankarage, D. et al. Functional characterization of a novel PBX1 de novo 624 missense variant identified in a patient with syndromic congenital heart disease. 625 Hum. Mol. Genet. 29, 1068–1082 (2020).
- 626 32. CP, C. et al. Pbx1 functions in distinct regulatory networks to pattern the great 627 arteries and cardiac outflow tract. Dev. Camb. Engl. 135, 3577-3586 (2008).
- 628 33. Espinoza-Lewis, R. A. et al. Shox2 is essential for the differentiation of cardiac 629 pacemaker cells by repressing Nkx2-5. Dev. Biol. 327, 376-385 (2009).

- 630 34. Munshi, N. V. Gene regulatory networks in cardiac conduction system 631 development. *Circ. Res.* **110**, 1525–1537 (2012).
- 35. Yang, T., Huang, Z., Li, H., Wang, L. & Chen, Y. P. Conjugated activation of
 myocardial-specific transcription of Gja5 by a pair of Nkx2-5-Shox2 co-responsive
 elements. *Dev. Biol.* 465, 79–87 (2020).
- 635 36. Puskaric, S. *et al.* Shox2 mediates Tbx5 activity by regulating Bmp4 in the
 636 pacemaker region of the developing heart. *Hum. Mol. Genet.* **19**, 4625–4633
 637 (2010).
- 638 37. Gannon, T. *et al.* Further delineation of the KAT6B molecular and phenotypic
 639 spectrum. *Eur. J. Hum. Genet.* 23, 1165–1170 (2015).
- 38. Zhang, L. X. *et al.* Further delineation of the clinical spectrum of KAT6B disorders
 and allelic series of pathogenic variants. *Genet. Med. Off. J. Am. Coll. Med. Genet.*22, 1338–1347 (2020).
- 39. Sevim Bayrak, C., Zhang, P., Tristani-Firouzi, M., Gelb, B. D. & Itan, Y. De novo
 variants in exomes of congenital heart disease patients identify risk genes and
 pathways. *Genome Med.* **12**, 9 (2020).
- 40. Lage, K. *et al.* Dissecting spatio-temporal protein networks driving human heart
 development and related disorders. *Mol. Syst. Biol.* 6, 381 (2010).
- 41. Del Monte-Nieto, G., Fischer, J. W., Gorski, D. J., Harvey, R. P. & Kovacic, J. C.
 Basic Biology of Extracellular Matrix in the Cardiovascular System. *J. Am. Coll. Cardiol.* **75**, 2169–2188 (2020).
- 42. Kathiriya, I. S., Nora, E. P. & Bruneau, B. G. Investigating the transcriptional control
 of cardiovascular development. *Circ. Res.* **116**, 700–714 (2015).
- 43. Lage, K. *et al.* Genetic and environmental risk factors in congenital heart disease
 functionally converge in protein networks driving heart development. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 14035–14040 (2012).
- 44. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD:
 predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47, D886–D894 (2019).
- 45. Samocha, K. E. *et al.* Regional missense constraint improves variant
 deleteriousness prediction. *bioRxiv* 148353 (2017) doi:10.1101/148353.
- 661 46. loannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the 662 Pathogenicity of Rare Missense Variants. *Am. J. Hum. Genet.* **99**, 877–885 (2016).
- 47. Qi, H. *et al.* MVP predicts the pathogenicity of missense variants by deep learning. *Nat. Commun.* **12**, 510 (2021).
- 48. Kaplanis, J. *et al.* Evidence for 28 genetic disorders discovered by combining
 healthcare and research data. *Nature* 586, 757–762 (2020).
- 49. Scardoni, G., Tosadori, G., Pratap, S., Spoto, F. & Laudanna, C. Finding the
 shortest path with PesCa: a tool for network reconstruction. *F1000Research* 4, 484
 (2015).
- 670
- 671
- 672

673 Data availability

- 674 The CRAM-level data from CHD patients used in this study can be accessed under
- 675 the following accession codes (European Genome-phenome Archive):
- 676 EGAD00001002200, EGAD00001000796, EGAD00001000797, EGAD00001000800,
- 677 EGAS00001000544, EGAS00001000775, EGAS00001000762. UK Biobank 50K
- 678 WES dataset freeze was accessed under the application number 44165.
- 679

680 Code availability

- 681 Pipelines for sample/variant quality control (QC), annotation, and burden testing are
- 682 available on GitHub: <u>https://github.com/enriquea/wes_chd_ukbb</u>.

684 Acknowledgements

685 This research was conducted using the UKBB Resource under application number 686 44165. We used data from the Deciphering Developmental Disorders (DDD) study. 687 The DDD study presents independent research commissioned by the Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome 688 689 Trust and the UK Department of Health, and the Wellcome Trust Sanger Institute. The 690 views expressed in this publication are those of the author(s) and not necessarily those 691 of the Wellcome Trust or the UK Department of Health. The authors wish to thank Prof. 692 Matthew Hurles (Sanger Institute, UK) for his significant contribution to this study. We 693 thank the KinderHerzen e. V. for providing research funding for this study. We thank 694 Prof. Dr. Christian Gilissen (RadboudUMC), Prof. Dr. Peter Krawitz (University Boon), 695 and collaborators from the Universitaetsklinikum Tuebingen (Prof. Dr. Stephan 696 Ossowski, Prof. Dr. Olaf Horst Rieß, Prof. Dr. Tobias Haack), for providing us with 697 Central European allele frequencies. This work was partly funded by PROCEED 698 project ERA PerMED joint Translational Call Initiative (DLR Funding reference 699 number: 01KU1919).



Figure 1. Analysis workflow for disease gene discovery. Quality control processes were conducted at the sample and variant levels. **(1)** Gene-set enrichment analysis was performed on the gene intolerance to missense and loss-of-function spectrum. **(2)** Gene-based case-control burden testing (Fisher's Exact test) was performed for high-confidence loss-of-function (hcLOF) and missense constrained variants (missC) independently. The per gene minimal *p-value* (*P*) from both analyses was set as the study-wide *p-value*, corrected for multiple testing using the Bonferroni and B-H methods. **(3)** Expression profiling of significant CHD genes differentially expressed on cardiac specific cell clusters **(4)** Digenic analysis was conducted by comparing the rate of mutations observed on cases compared to controls. All analysis were stratified by syndromic status (aCHD, sCHD and nsCHD) vs control.

Main figures





Figure 2. Enrichment analysis across the LOF constraint gene spectrum. Protein-coding genes were binned based on the LOEUF metric as proposed by gnomAD. Every bin contains ~1,900 genes. Top bins (1, 2) contain genes with the highest intolerance to loss-of-function. a) Enrichment analysis comparing aCHD vs controls. b) Enrichment analysis stratified by syndromic status (sCHD and nsCHD) vs controls in the top constraint LOF bin (1). The x-axis indicates the constraint bins; the y-axis shows the Odd Ratios (OR) and the 95% confidence interval.



Figure 3. Log-transformed minimal p-value (P) per gene (y-axis) against its chromosomal location (xaxis). Red dashed line denotes the threshold for genes reaching exome-wide significance (Bonferroni adjusted P < 0.05); grey dashed line marks the threshold for genes reaching suggestive exome-wide significance (FDR 5%). a) Burden analysis of sCHD vs controls; b) burden analysis of nsCHD vs controls.





Figure 4. Logistic regression-based enrichment analysis of differentially expressed genes (DEGs) in cardiac-specific cell clusters for high-confidence loss-of-function variants (hcLOF). The analysis was stratified by syndromic status (aCHD, sCHD and nsCHD). The x-axis denotes the Odd Ratio (OR) and the 95% confidence interval. P-values were adjusted using the Bonferroni method (0.05 / 45 tests) to assess significant enrichment. Cardiac cell clusters C0, C3, C5, C7 and C14, show significant enrichment when analysing aCHD vs controls. The enrichment observed in clusters C7 and C14 showed a major contribution of sCHD. In comparison, cluster C0 provided the major contribution to nsCHD.



Figure 5. Case-control enrichment analysis at the digenic level using the RareComb framework. (a) Proportion of digenic pairs contributing to syndromic and non-syndromic CHD identified at FDR 1%. (b) Comparison of the distribution of LOEUF metric (at gene level) between syndromic and non-syndromic. The analysis was performed on genes observed in just one digenic pair. (c) Overlap of genes forming digenic interactions with known CHD genes. (d) Protein-protein interaction (PPI) network analysis of digenic genes for sCHD and nsCHD (PPI networks with annotated gene names are shown in Supplemental Figure 10). (e) Overlap between digenic pairs and first-degree interactors for sCHD and nsCHD in its respective PPI networks. (f) Length of the shortest path observed between genes forming a digenic pair in a PPI network.

Supplemental figures



Supplemental Figure 1. Enrichment analysis across the missense constraint gene spectrum. Proteincoding genes were binned based on the MOEUF metric as proposed by gnomAD. Every bin contains ~1,900 genes. Top bins (1, 2) contain the genes with the highest intolerance to missense variation. a) Enrichment analysis per bin for aCHD vs controls are shown. b) Enrichment analysis stratified by syndromic status (sCHD and nsCHD) vs controls in the top constraint MOEUF bin (1). The x-axis indicates the constraint bins; the y-axis shows the Odd Ratios (OR) and the 95% confidence interval. hcLOF: high-confidence loss-of-function variants; missC: missense constrained variants; syn: synonymous variants.





Supplemental Figure 2. ROC analysis of pathogenicity prediction scores (CADD, REVEL, MVP and MPC). The analysis was performed on a balanced set of benign (true negative) and likely pathogenic (true positive) variants from the ClinVar database within known CHD genes. The top panels show the results for LOF constraint genes (LOUEF < 0.35). The bottom panels show the results for LOF non-constraint genes (LOUEF >= 0.35).



Supplemental Figure 3. Quantile-quantile plots. Expected vs observed p-values for synonymous variants stratified by syndromic status (MAF 0.1%). Q-Q plots for aCHD, sCHD and nsCHD vs controls are shown.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.23.23300495; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in





Supplemental Figure 4. Expression pattern of CHD genes in different tissues (Heart, Brain, Liver and Kidney). X-axis denotes gene p-value bins. P-value refers to the minimal p-value (P) observed in the gene-based enrichment analysis for rare hcLOF and missC variants. The gene association analysis was performed by comparing all CHD probands (aCHD) vs controls. Y-axis denotes tissue-specific percentile rank of mean expression. Averaged expression was computed for samples between 4-8 weeks-post-conception (developmental stage). More significant genes (blue box) in the CHD casecontrol analysis showed the higher expression rank (e.g., Heart, Brain, and Kidney). Mean comparisons between bins were computed using the Wilcoxon test (alternative: greater; reference group (red box): genes with P > 0.05 in the case-control analysis). ns: p > 0.05; *: $p \le 0.05$; **: $p \le 0.01$; ***: $p \le 0.01$; **: $p \le 0.01$; **: $p \le 0.01$; ***: $p \le 0.01$; **: $p \ge 0.01$; * 0.001; ****: p <= 0.0001.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.23.23300495; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Supplemental Figure 5. Tissue-specific expression pattern of CHD genes identified in the case-control analysis, stratified by syndromic status (syndromic (sCHD) and non-syndromic (nsCHD) vs controls). Only genes with unadjusted P < 0.005 in the case-control analysis are included. X-axis denotes the probands used in the case-control analysis (sCHD or nsCHD vs controls). Y-axis denotes tissue-specific percentile rank of mean expression. Averaged expression was computed among samples between 4-8 weeks-post-conception (developmental stage). Mean comparisons between groups were computed using the Wilcoxon test (two-sided). No significant difference was observed in the Heart for sCHD and nsCHD genes (P > 0.05), compared to other tissues (e.g. brain, liver and kidney, P < 0.05).



Supplemental Figure 6. Logistic regression-based enrichment analysis of differentially expressed genes (DEGs) in cardiac-specific cell clusters for missense constrained variants (missC). The analysis was stratified by syndromic status (aCHD, sCHD and nsCHD). The x-axis denotes the Odds Ratio (OR) and the 95% confidence interval. P-values were adjusted using the Bonferroni method (0.05 / 45 tests) to assess for significant enrichment.





Supplemental Figure 7. Logistic regression-based enrichment analysis of differentially expressed genes (DEGs) in cardiac-specific cell clusters for synonymous variants. The analysis was stratified by syndromic status (aCHD, sCHD and nsCHD). The x-axis denotes the Odds Ratio (OR) and the 95% confidence interval. P-values were adjusted using the Bonferroni method (0.05 / 45 tests) to assess for significant enrichment.



с С

++

+

(Supplemental Figure 8. Legend on next page)

a)

Supplemental Figure 8. Gene Ontology (GO) enrichment analysis of differentially expressed genes (DEGs) in cardiac-specific cells with unadjusted P < 0.01 in the case-control burden analysis. a) C7: atrial cardiomyocytes cells, b) C0: capillary endothelium, c) C5: smooth muscle cells and d) C10: endothelium and pericytes cells. Only clusters with at least one GO term with *FDR* < 1% are shown. For every GO term, the overlapping DE genes (+) are shown.





Supplemental Figure 10. Protein-protein interaction network for syndromic and non-syndromic CHD digenic genes. Nodes are labeled with the corresponding gene name and annotated with the specific biological process.

Supplemental Figure 11. Digenic pairs are scattered across protein-protein interaction (PPI) network. Examples of non-syndromic digenic pairs and its shortest paths are highlighted in the network. The median of the shortest path between non-syndromic digenic pairs was six (violin plot).

Supplemental Figure 12. Top enriched genes (unadjusted *P* < 0.001, case-control Fisher Exact test) found differentially expressed in at least one cardiac-specific cell cluster. The left plot shows the gene/cluster overlap and highlights the variant category with the highest enrichment (blue: hcLOF, red: missC). The x-axis denotes de cardiac clusters; the y-axis indicates the genes and the CHD category analysed (s: sCHD, n: nsCHD). The right plot shows the log-transformed P (x-axis) and the FDR significant level per gene. Six genes showed FDR < 10%: NOTCH1, FLT4, PBX1, SHOX2, KAT6B and CHD7. C0: Capillary endothelium, C1: Ventricular cardiomyocytes, C2: Fibroblast-like (related to cardiac skeleton connective tissue), C3: Epicardium-derived cells, C4: Fibroblast-like (related to smaller vascular development), C5: Smooth muscle cells, C7: Atrial cardiomyocytes, C8: Fibroblast-like (related to larger vascular development), C9: Epicardial cells, C10: Endothelium/pericytes/adventia, C11: Erythrocytes (class II), C12: Myoz2-enriched cardiomyocytes, C14: Cardiac neural crest cells & Schwann progenitor cells.